

# Poorer treatment response among HIV/HCV-co-infected patients treated with combined HIV/HCV therapy

**Colette Smit<sup>1</sup>, Luuk Gras<sup>1</sup>, Ard van Sighem<sup>1</sup>, Thomas Ruys<sup>2</sup>, Joep Lange<sup>2</sup>, Frank de**

**Wolf<sup>1,3</sup>** <sup>1</sup> HIV Monitoring Foundation, Amsterdam, The Netherlands, <sup>2</sup> CINIMA, Academic Medical Centre, Amsterdam, The Netherlands, <sup>3</sup> Department of Infectious Diseases Epidemiology, Imperial College School of Medicine, London, United Kingdom


**Objective:** to describe differences in all-cause mortality and immunologic response between HCV co-infected patients receiving combined HCV/HIV treatment, HCV co-infected patients receiving HAART and mono-HIV infected HAART treated patients

**Combined HIV/HCV therapy:**  $\geq 3$  antiretroviral drugs from  $\geq 2$  drug classes+ temporary (peg) interferon during HIV treatment

patients groups:

- 1) HCV-negative receiving HAART
- 2) HIV/HCV co-infection receiving combined HIV/HCV treatment
- 3) HIV/HCV co-infection receiving HAART

# All-cause mortality among HIV/HCV co-infected patients treated with HAART



hcvstat



no HCV infection  
HIV/HCV-co-infection, combined HIV/HCV therapy  
HIV/HCV-co-infection, HAART without anti-HCV treatment

---

**Hazard ratios of time to death and immunologic and virologic success.**

	<b>Death<sup>^</sup> HR (95% CI)</b>	<b>Increase CD4 cell count <math>\geq</math> 100 cells/<math>\mu</math>L*<sup>^</sup> OR (95% CI)</b>	<b>Undetectable HIV RNA levels*<sup>^</sup> OR (95% CI)</b>
<b>Non co-infected</b>	1	1	1
<b>HCV co-infection receiving combined HCV/HIV treatment</b>	1.73 (0.69-4.12)	0.74 (0.27-1.98)	0.43 (0.16-1.18)
<b>HCV co-infection receiving HAART</b>	1.60 (1.18-2.18)	0.77 (0.64-0.93)	1.23 (0.95-1.60)

**\* 6 months after HAART initiation, <sup>^</sup> adjusted**

---

## **Conclusions**

- HCV co-infection increases mortality in HIV-infected patients using HAART.**
- Only a small number of patients is receiving combined HIV/HCV treatment.**
- Among HIV/HCV co-infected patients, early immunologic response seems less favourable compared to HIV only infected patients.**